Nuvo's second technology - an immune system regulation platform - is based on WF10, a solution of OXO-K993 containing stabilized chlorite ions.

The immune system provides an essential defence to micro organisms, cancer and substances it sees as foreign and potentially harmful. The Company's immune system regulation platform, focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function.

All immune system regulation research is carried out through Dimethaid AG in which the Company has a 60% interest. Research and development activities related to WF10 will be conducted at Nuvo Research GmbH, a wholly owned subsidiary of Dimethaid AG.